Discover the latest drugs and treatment options in the Psoriasis Pipeline. Dive into DelveInsight's comprehensive report ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and ...

Discover a study that assessed the risk of hospitalisation for serious infections based on different categories of systemic ...

A new cohort study published in Journal of American Medical Association suggests that biologics targeting IL-12, IL-23, and ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics used to treat psoriasis, said Strober. The momentum can be traced to an ...

The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting interleukin (IL)-12, IL-23, or IL-17 were associated with a lower rate of serious ...

Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...

In a murine model, a proprietary protease enzyme stabilized platform demonstrated successful delivery of infliximab, a tumor necrosis factor-alpha (TNF-α) inhibitor, in serum with concentrations ...

Infliximab, a TNF-α inhibitor, is a widely used biologic ... psoriatic arthritis, and plaque psoriasis. Globally, infliximab (including biosimilars) generated approximately $6.3 billion in ...

Disease activity was followed with Psoriasis Area and Severity Index ... “many patients with joint pain are put on IL-17 blockers or TNF [tumor necrosis factor] blockers, not only IL-23 blockers ...